Abstract
A novel T-type calcium channel blocker, 4-amino-1-{4-[(4-chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-butan-1-one (HYP-10) has been synthesized, and the compound has shown promise as both a nociceptive and inflammatory pain reliever as well as an analgesic in a rat neuropathic pain model. A quantification method was developed for the determination of HYP-10 in rat plasma. After simple protein precipitation with methanol, HYP-10 and the internal standard, methaqualone were chromatographed on a reversed-phase column and detected by liquid chromatography/tandem mass spectrometry with electrospray ionization. The accuracy and precision of the assay were in accordance with FDA regulations for validation of bioanalytical methods. This method was applied to measure the plasma HYP-10 concentration after a single intravenous administration of the compound in rats.
Original language | English |
---|---|
Pages (from-to) | 568-571 |
Number of pages | 4 |
Journal | Journal of Pharmaceutical and Biomedical Analysis |
Volume | 54 |
Issue number | 3 |
DOIs | |
State | Published - 20 Feb 2011 |
Bibliographical note
Funding Information:This work was supported by grant from the Brain Korea 21 program and grant No. R15-2006-020 from the NCRC program of the MEST and the NRF through the Center for Cell Signaling & Drug Discovery Research at Ewha Womans University .
Keywords
- HYP-10
- LC-MS/MS
- Novel T-type calcium channel blocker
- Rat plasma